There is an ongoing debate as to whether SARS-CoV-2 antibodies can be found in patients who have recovered from COVID-19 disease. Currently, there is no consensus on whether the antibodies, if present, are protective. Our regular measurements of SARS-CoV-2 antibodies, starting in July 2020, have provided us with the opportunity of becoming acquainted with the five different immunoassays. A total of 149 patients were enrolled in our study. We measured the samples using each immunoassay, then performing a virus neutralization test and comparing the results of SARS-CoV-2 antibodies with this test. We observed that the production of neutralizing antibodies is age-dependent. Elderly patients have a higher proportion of high neutralizing titers than young patients. Based on our results, and in combination with the literature findings, we can conclude that the serological SARS-CoV-2 antibody measurement is a helpful tool in the fight against COVID-19. The assays can provide information about the patient’s previous contact with the virus. Anti-spike protein assays correlate well with the virus neutralization test and can be used in the screening of potential convalescent plasma donors.
Purpose: To assess short-term safety after routine same-day seasonal influenza and COVID-19 vaccination in community-dwelling adults aged 65 years and older, predominantly very old, and to identify factors associated with adverse events within 48 h. Methods: We conducted a prospective observational cohort study in a hospital-based infectious diseases department and a collaborating outpatient clinic in the Czech Republic, enrolling adults aged 65 years and older vaccinated between 1 September and 30 November 2025. Participants completed 48 h symptom diaries and measured body temperature at 24 and 48 h. We compared local reactions between vaccine injection sites within individuals and used regression models to examine demographic and clinical correlates of adverse events and the predictive value of 24 h temperature. Results: The cohort included 169 participants, 75.1% of whom were women, with a mean age of 84.3 years and substantial multimorbidity. Within 48 h, 44.4% reported at least one adverse event, most reactions were mild, and no participant had fever at 48 h. Local reactions were more frequent at the COVID-19 than the influenza injection site. Higher comorbidity count predicted any adverse event (odds ratio 1.3, 95% CI 1.0–1.6), and prior COVID-19 infection predicted systemic adverse events (odds ratio 2.2, 95% CI 1.1–4.4). Higher body temperature at 24 h was associated with higher counts of total, systemic, and local adverse events at 48 h, with the strongest association observed for systemic symptoms (β = 0.4, p < 0.001). Conclusion: Same-day influenza and COVID-19 vaccination was generally well tolerated in very old, medically complex adults, supporting coadministration with anticipatory counselling for those with higher comorbidity burden or prior COVID-19 infection.
A group of 110 patients from the West Bohemian region who had been infected with COVID-19 was monitored for the purposes of this study. We focused on cases of mild or moderate COVID-19; statistically the most likely to occur. Day zero was defined as the day on which a positive PCR test was first established. The mean length of observation was 6.5 months, the maximum length 12 months. The first blood samples were taken from a smaller cohort during the 1–3 months following the first positive PCR test. We assumed that SARS-CoV-2 antibodies would be present during this period and therefore a limited number of samples were taken for the purpose of detecting antibodies. More samples were collected, starting 4 months after the first positive PCR test. A subsequent set of blood samples were drawn, mostly 6 months after the first ones. Our study confirmed the presence of total IgG SARS-CoV-2 antibodies up to 1 year after the onset of the disease. The peak of antibody production was observed in the third month after the first positive PCR test. A mathematical estimate of the median duration of antibody positivity was calculated to be 18 months from the onset of the COVID-19 infection.
31 December 2022 in Central European Journal of Public Health
Since December 2019, the new SARS-CoV-2 coronavirus causes COVID-19 disease worldwide, which occurs mainly in unvaccinated elderly and polymorbid patients with a more severe course and increased risk of complications and death. Vaccination and...
26 October 2025 in Journal of Workplace Behavioral Health